You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Vertex gets early OK for new drug

Kalydeco to treat certain patients with cystic fibrosis

Acting three months before its scheduled decision date, the Food and Drug Administration yesterday approved a drug developed by Vertex Pharmaceuticals Inc. to treat some patients suffering from cystic fibrosis, a rare and often fatal genetic disease.

The drug, called Kalydeco, is the second therapy from the Cambridge company to receive the FDA’s blessing in the past eight months. Its first drug, Incivek, was approved last May to combat the hepatitis C virus.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week